Publications by authors named "K Oliva"
Background: Colorectal surgical procedures can have a significant impact on quality-of-life (QoL), functional and symptom outcomes. This retrospective study conducted in a tertiary care center evaluated the influence of four colorectal surgical procedures on patient-reported outcome measures (PROMs).
Methods: 512 patients undergoing colorectal neoplasia surgery between June 2015 and December 2017 were identified via the Cabrini Monash Colorectal Neoplasia database.
Purpose: In 2019, in Australia, there were 500,000 people aged 85 and over. Traditionally, clinicians have adopted the view that surgery is not desirable in this cohort due to increasing perioperative risk, perceived minimal clinical benefit, and shortened life expectancy. This cohort study is aimed at investigating postoperative outcomes from elective and non-elective colorectal cancer surgery in patients aged 80 and over.
View Article and Find Full Text PDFBackgrounds: Magnetic resonance imaging is the primary method for local staging in rectal cancer patients. Administration of intravenous (IV) hyoscine butylbromide is thought to improve accuracy, but there are contraindications and potential adverse effects. The aim was to assess the efficacy of IV hyoscine butylbromide on the accuracy of MRI rectal cancer staging of T2 and T3 rectal cancers.
View Article and Find Full Text PDFBackground: Anastomotic leak after restorative surgery for rectal cancer is a major complication and may lead to worse long-term oncological and survival outcomes.
Objective: The purpose of this study was to identify risk factors associated with anastomotic leak and to assess the perioperative and long-term oncological impact of anastomotic leak in our cohort of patients with rectal cancer.
Design: A retrospective analysis was performed on data from the prospectively maintained Cabrini Monash colorectal neoplasia database.
Article Synopsis
- A study looked at a surgery called cytoreductive nephrectomy (CN) for patients with advanced kidney cancer who received immunotherapy and wanted to see how it affects their survival.
- The research included 367 patients, and those who had CN along with immunotherapy lived longer (about 56.3 months) compared to those who only had immunotherapy (about 19.1 months).
- The results suggest that CN can help patients with metastatic kidney cancer live longer when combined with immunotherapy, so doctors might consider it for some patients.